You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
This Podcast features a conversation with the authors of a Report published in the March 30th issue of Science Magazine. David Sabatini and Joseph Baur discuss how the drug rapamycin affects longevity and insulin sensitivity. Rapamycin is an immunosuppressant that is used to prevent transplant rejection. It can also extend the life span of many animals, but long-term rapamycin treatment impairs the sensitivity to insulin and leads to glucose intolerance. In a new collaborative study published in Science, Sabatini and Baur’s groups have dissected the mechanism of rapamycin action and found that its effects on life span and insulin sensitivity are mediated by different molecular targets. Their research also overturned the widely held belief that rapamycin only inhibits one of two related protein complexes.
